nsclc

Documents about nsclc

• Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations#245521ClinicalTrials.gov
• Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)#146469ClinicalTrials.gov
• Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial#872778ClinicalTrials.gov
• A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced#907042ClinicalTrials.gov
• A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)#451455ClinicalTrials.gov
• RGL-270 + ICI in Advanced NSCLC#454063ClinicalTrials.gov
• Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC#314317ClinicalTrials.gov
• Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients#683098ClinicalTrials.gov
• Selumetinib in Combination With Gefitinib in NSCLC Patients#828813ClinicalTrials.gov
• EMPATHY NSCLC: European Registry for Plasma-Based Molecular Profiling in Advanced NSCLC Patients#890026ClinicalTrials.gov
• Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)#910064ClinicalTrials.gov
• Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)#903323ClinicalTrials.gov
• WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC#825131ClinicalTrials.gov
• Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC#900397ClinicalTrials.gov
• Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC#904338ClinicalTrials.gov
• Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC#912159ClinicalTrials.gov
• Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases#804177ClinicalTrials.gov
• Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC#898038ClinicalTrials.gov
• Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo#683094ClinicalTrials.gov
• Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients#868062ClinicalTrials.gov
• Afatinib Plus Nimotuzumb for NSCLC#886259ClinicalTrials.gov
• Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection#890778ClinicalTrials.gov
• Whole Genomic Landscape of Advanced EGFR-mutant NSCLC#908989ClinicalTrials.gov
• Pembrolizumab as First-line Treatment for Advanced NSCLC Complicated With COPD#300258ClinicalTrials.gov
• Coagulation System In STereotactic Radiotherapy Of NSCLC#900130ClinicalTrials.gov
• Combination of Metformin With Gefitinib to Treat NSCLC#889323ClinicalTrials.gov
• Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases#180404ClinicalTrials.gov
• Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable NSCLC#332750ClinicalTrials.gov
• Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC#849261ClinicalTrials.gov
• Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients#898910ClinicalTrials.gov
• Study for Patients With Non Small Cell Lung Cancer (NSCLC)#805731ClinicalTrials.gov
• Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer#825945ClinicalTrials.gov
• A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations#904116ClinicalTrials.gov
• Immunotherapy With Non-Ablative Radiation in Previously Untreated Patients With Stage IV NSCLC#238115ClinicalTrials.gov
• A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC#831942ClinicalTrials.gov
• Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC#835783ClinicalTrials.gov
• Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation#893053ClinicalTrials.gov
• Validation of the TheraSure CNI-Monitor Under Immuno-checkpoint-therapy (Hereinafter: "Immunotherapy") in NSCLC in Palliative Therapy#343836ClinicalTrials.gov
• Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy#451462ClinicalTrials.gov
• Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation#862235ClinicalTrials.gov
• A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC#876256ClinicalTrials.gov
• Atezolizumab Plus Bevacizumab in First Line NSCLC Patients#879873ClinicalTrials.gov
• Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation#884164ClinicalTrials.gov
• Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure#136302ClinicalTrials.gov
• Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors#811500ClinicalTrials.gov
• LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)#810833ClinicalTrials.gov
• QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC#865786ClinicalTrials.gov
• Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma#889345ClinicalTrials.gov
• Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC#253010ClinicalTrials.gov
• Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy#451468ClinicalTrials.gov